TMLabs represents the internal research and development function of Talking Medicines, designed to advance the application of data science within the life sciences sector. Positioned as a centre of excellence, it focuses on building and refining proprietary analytical models that interpret large volumes of real-world healthcare dialogue.
At its core, TMLabs is structured to support the continuous development of predictive intelligence tools. By training and testing models on complex, unstructured datasets, particularly those derived from healthcare professionals and patient conversations, the unit aims to generate insights that can be applied across commercial and clinical decision-making.
The initiative underpins two of the company’s key solution areas, enabling them to extract value from otherwise fragmented or inaccessible data sources. For investors, this integration suggests a deliberate effort to embed research capabilities directly into revenue-generating products, rather than treating innovation as a separate or purely experimental function.
Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.
